Evaluation of liver and renal function before and after administration of methotrexate (MTX) is recommended in the treatment of molar pregnancy, but the necessity of performing these tests during treatment of ectopic pregnancy (EP) is not clear. The aim of this study was to evaluate the changes of creatinine and AST levels before and after treatment with double (DD) and multiple (MD) doses of MTX in patients with Ep. Methods: This retrospective cross-sectional study performed on 152 patients with an EP during 2007-2013 in Al-Zahra hospital (Rasht). Seventy six patients received DD and 76 cases were treated with MD of MTX. The success rate, side effects of MTX and changes in creatinine and AST levels were compared between the two groups. Results: The mean changes in creatinine level was 0.06±0.08 and 0.16±0.13 in DD and MD groups, respectively and the difference between the two groups was statistically significant (p=0.002). The mean changes in AST level was 5.06±2.47 and 9.63±5.5 in DD and MD groups, respectively which was statistically significant (p=0.002). The success rates were 65.8% and 86.8% in DD and MD groups, respectively with statistically significant difference (p=0.002). The side effects rates were 13.2% and 32.9% in DD and MD groups, respectively with statistically significant difference (p=0.004). Conclusion: It seems that administration of MD of MTX in EP patients leads to an increase in success rate of treatment but also it causes considerable increase in creatinine and AST levels.

